Why does the translational pipeline from AD animal models to human trials have such high attrition, and how can preclinical-to-clinical translation be improved?

Despite high crowding (0.919), only one Phase II trial is currently recruiting. This suggests fundamental issues in translating mechanistic targets from rodent models to human biology remain an unsolved problem.